Lates News

Ge Li Pharmaceutical announced on the Hong Kong Stock Exchange that the first batch of obese or overweight participants have been dosed with ASC30, a small molecule oral GLP-1R agonist, in the 13-week Phase IIa study in the United States. In the Phase Ib study in the United States, ASC30 once daily oral tablets showed a mean weight reduction of up to 6.5% relative to baseline after 4 weeks of treatment following placebo calibration. The top-line data for the 13-week Phase IIa study of ASC30 oral tablets is expected to be obtained in the fourth quarter of 2025.